STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Qualigen Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

AIxCrypto Holdings, Inc. (QLGN) reported that Nasdaq notified the company it had failed to comply with Listing Rule 5635(b), which requires shareholder approval before an issuance of securities that results in a change of control. The issue related to a $41,000,000 PIPE financing that closed on September 29, 2025, involving 337,432 shares of common stock and 17,783 shares of Series B Convertible Preferred Stock sold to investors including Faraday Future Intelligent Electric Inc.

Nasdaq determined that this financing, together with significant board and management changes involving Faraday-affiliated individuals, constituted a change of control without prior shareholder approval. The company later obtained majority shareholder approval, and Nasdaq informed it that the deficiency was remediated and the matter closed, with no impact on the current listing of its common stock. Separately, on November 19, 2025, Nasdaq confirmed the company is in compliance with Listing Rule 5550(b)(1) on stockholders’ equity, but the company will remain under a one-year Panel Monitor period.

Positive
  • None.
Negative
  • None.

Insights

Nasdaq found a change-of-control approval lapse, now cured but under monitoring.

AIxCrypto Holdings completed a PIPE financing on September 29, 2025, raising $41,000,000 through 337,432 common shares and 17,783 Series B Convertible Preferred shares sold to investors including Faraday Future Intelligent Electric Inc.. Nasdaq later concluded this, combined with multiple Faraday-linked board and executive appointments, triggered Listing Rule 5635(b) change-of-control approval requirements.

The company did not obtain shareholder approval before closing but subsequently secured majority shareholder consent. Nasdaq’s staff stated the deficiency under Rule 5635(b) has been remediated and the matter is closed, and the common stock’s listing remains unaffected. This points to a governance and process issue that has been addressed, but highlights the importance of aligning capital-raising structures and control shifts with listing rules.

On November 19, 2025, Nasdaq also confirmed compliance with the Equity Rule 5550(b)(1), while placing the company under a one-year Panel Monitor. During this period, any future equity shortfalls would go straight to a Nasdaq Hearing Panel rather than a staff remediation process, so continued adherence to equity and governance standards will be important for maintaining the listing status.

false 0001460702 0001460702 2025-11-18 2025-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2025

 

AIxCrypto Holdings, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37428   26-3474527
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

5857 Owens Avenue, Suite 300    
Carlsbad, California   92008
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (760) 452-8111

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   QLGN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

Non-Compliance with Nasdaq Listing Rule 5635(b)

 

On November 18, 2025, the Company received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with Nasdaq’s shareholder approval requirements set forth in Nasdaq Listing Rule 5635(b) (the “Rule”), which requires shareholder approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company, in connection with the Company’s private placement transaction (the “PIPE Financing”) that closed on September 29. 2025 (the “Closing Date”).

 

Nasdaq’s Letter has no effect on the listing of the Company’s Common Stock (as defined below) on The Nasdaq Capital Market.

 

On September 29, 2025, the Company consummated an offering (the “Offering”) in which with certain investors, including Faraday Future Intelligent Electric Inc. (“Faraday”) pursuant to which the investors agreed to purchase $41,000,000 in cash including 337,432 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and 17,783 shares of a newly created Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Stock”). The purchase price of the Common Stock was $2.246 per share and the purchase price for the Series B Stock was $1,000 per share. On the Closing Date, the shares of Common Stock and Series B Stock were allocated among the investors so that no purchaser’s ownership of Common Stock exceeded 19.99% of the number of shares outstanding.

 

The Letter recites that, on and after the Closing Date, significant changes in the composition of the Company’s senior management and board of directors (the “Board”) occurred, including the following: (1) on September 26, 2025, the Board appointed a new independent member of the Board pursuant to the Lead Investor Agreement with Faraday, dated September 19, 2025, to which three of the Company’s five directors resigned; (2) on October 2, 2025, two new members were appointed to the Board, one of which also serves as a board member of Faraday and the other serves as the Head of Operations & Finance Director of an affiliate of Faraday, thus constituting 40% of the five-member Board; and (3) on October 2, 2025, the Company appointed Jiawei Wang as the Co-Chief Executive Officer and Koti Meka as the Chief Financial Officer of the Company, who also serve as the President and Chief Financial Officer of Faraday, respectively.

 

The Letter states that the Company was required to obtain shareholder approval under the Rule prior to the issuance of shares in the PIPE Financing, which the Letter states resulted in a change of control of the Company, but that the Company failed to do so. The Company disputes that the appointment of Kevin Chen on September 26, 2025 was connected to the Offering.

 

The Letter also notified the Company of the Staff’s determination that having obtained majority shareholder approval from the Company’s shareholders of record prior to the Offering, the Company had remediated the deficiency and regained compliance with the Rule, and the matter is now closed, as further described therein.

 

The Company, by filing this Form 8-K, discloses its receipt of the notification from Nasdaq in accordance with Nasdaq Listing Rule 5810(b)

 

Compliance with Nasdaq Listing Rule 5550(b)(1)

 

On November 19, 2025, the Company received formal notice from the Staff of Nasdaq that the Company was in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing of its securities on the Nasdaq Capital Market tier. The Company was also notified that it will remain subject to a “Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for review by the Satff and must instead request a hearing before the Nasdaq Hearing Panel (the “Panel”) to address the deficiency, with such request staying any further action with respect to the listing of the Company’s securities on Nasdaq pending completion of the hearing process.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AIxCrypto Holdings, Inc.
   
     
Date: November 21, 2025 By:  /s/ Kevin A. Richardson II
  Name: Kevin A. Richardson II
  Title: Co-Chief Executive Officer

 

 

FAQ

What Nasdaq rule did AIxCrypto Holdings (QLGN) initially fail to comply with?

AIxCrypto Holdings initially failed to comply with Nasdaq Listing Rule 5635(b), which requires shareholder approval before issuing securities that result in a change of control of the company.

What were the key terms of AIxCrypto Holdings' September 2025 PIPE financing?

On September 29, 2025, AIxCrypto Holdings completed a PIPE financing in which investors, including Faraday Future Intelligent Electric Inc., agreed to purchase $41,000,000 in securities, consisting of 337,432 shares of common stock and 17,783 shares of Series B Convertible Preferred Stock.

Did Nasdaq’s non-compliance letter affect the listing of QLGN common stock?

No. The company disclosed that Nasdaq’s letter regarding Rule 5635(b) had no effect on the listing of its common stock on The Nasdaq Capital Market, and Nasdaq later confirmed the deficiency was remediated and the matter closed.

How did AIxCrypto Holdings regain compliance with Nasdaq Listing Rule 5635(b)?

Nasdaq’s staff noted that AIxCrypto Holdings obtained majority shareholder approval from shareholders of record prior to the Offering, which remediated the deficiency under Rule 5635(b) and brought the company back into compliance.

What changes in management and the board did Nasdaq associate with a change of control at AIxCrypto?

Nasdaq cited several changes: three of five directors resigned and a new independent director was appointed pursuant to an agreement with Faraday; two additional directors with roles at Faraday or its affiliate joined the board; and Jiawei Wang and Koti Meka, who also hold senior positions at Faraday, became Co-CEO and CFO of AIxCrypto, respectively.

Is AIxCrypto Holdings currently in compliance with Nasdaq’s equity requirements?

Yes. On November 19, 2025, Nasdaq notified AIxCrypto that it is in compliance with Listing Rule 5550(b)(1) regarding stockholders’ equity, though the company will be subject to a one-year Panel Monitor period.

What does the Nasdaq Panel Monitor mean for AIxCrypto Holdings (QLGN)?

Under the one-year Panel Monitor, if AIxCrypto falls out of compliance with the Equity Rule 5550(b)(1) again, it will not be able to submit a staff remediation plan and would instead need to request a hearing before a Nasdaq Hearing Panel to address any deficiency.
Qualigen Therapeutics Inc

NASDAQ:QLGN

QLGN Rankings

QLGN Latest News

QLGN Latest SEC Filings

QLGN Stock Data

6.53M
2.62M
2.17%
0.72%
2.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
CALIFORNIA